Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11252MR)

This product GTTS-WQ11252MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11252MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15961MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ3651MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ264MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ11824MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ15242MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ5243MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ11393MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ3662MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW